Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neurology

Treatment Strategy: Medication vs. Watchful Waiting

At a Glance

For many children with SeLECTS, 'watchful waiting' is the preferred approach because seizures are often infrequent, nocturnal, and naturally outgrown by adolescence. Daily anti-seizure medications are typically reserved for frequent seizures, daytime episodes, or signs of cognitive decline.

Choosing whether to start a daily medication for a child with SeLECTS is a highly personal decision. Because the condition is self-limited—meaning it typically resolves on its own by age 15 or 16—the medical goal is to manage symptoms rather than “cure” the epilepsy [1][2].

The “Watchful Waiting” Approach

For many children with SeLECTS, the standard of care is watchful waiting (observation without daily medication) [1]. During this period, you will typically see your neurologist every 6 to 12 months. This approach is often preferred because:

  • Seizures are Infrequent: Many children have only a few seizures in their entire lives [1].
  • Seizures are Nocturnal: If seizures only happen during sleep, they rarely interfere with school, sports, or social life [3][4].
  • Avoiding Side Effects: All anti-seizure medications (ASMs) carry a risk of side effects, such as irritability or fatigue. Doctors often weigh the “burden” of a daily pill against the “burden” of a rare nighttime seizure [5][6].

When Medication is Recommended

While waiting is common, doctors may recommend starting an Anti-Seizure Medication (ASM) if specific clinical signs appear [7]:

  1. Frequent Seizures: If episodes are happening often enough to disrupt sleep or cause significant family anxiety.
  2. Daytime (Diurnal) Seizures: Seizures during the day can pose safety risks (e.g., during swimming) or cause social distress at school [3].
  3. Cognitive or Language Decline: If a child shows sudden, new struggles with speech, reading, or focus, doctors may decide to treat the brain’s electrical activity more aggressively [8][9].

Common Medications: US vs. Europe

The choice of medication often depends on where you live. In the United States, common first-choice medications include:

  • Levetiracetam (Keppra): A very common first-choice medication [10]. While standard versions are usually dosed twice daily, doctors sometimes prescribe an extended-release (XR) version or a specific evening dose to target purely nocturnal seizures. It is effective but can sometimes cause mood changes or irritability. Note: If irritability occurs, doctors often recommend adding a Vitamin B6 supplement or adjusting the dose before abandoning the drug entirely.
  • Oxcarbazepine (Trileptal): Frequently used for focal seizures [11]. It is generally well-tolerated but requires monitoring of sodium levels. Crucial Warning: In some children with SeLECTS, sodium channel blockers like oxcarbazepine can paradoxically make the “sleep spikes” worse and trigger a severe cognitive decline (pushing the child toward the ESES spectrum) [12]. If you start this medication, monitor your child closely for sudden drops in school performance or loss of language skills.
  • Valproate (Depakote): Very effective at stopping both seizures and EEG spikes, but used less frequently due to a broader side-effect profile [13].

In Europe, a medication called Sulthiame (Ospolot) is a standard first-line treatment for SeLECTS. It is particularly effective at reducing the “spikes” on an EEG. However, Sulthiame is not FDA-approved in the US and is generally unavailable to American patients.

Treating Seizures, Not Spikes

A key concept in SeLECTS is that doctors typically treat the clinical seizures (the physical events) rather than the interictal spikes (the electrical activity on the EEG) [1][14]. A child may have an EEG that looks “busy” with many spikes, but if they are not having seizures and are doing well in school, medication may not be necessary [14][15]. The spikes are expected to disappear on their own as the brain matures [1].

Common questions in this guide

Why do doctors recommend watchful waiting for SeLECTS?
Watchful waiting is often recommended because SeLECTS is a self-limited condition that children typically outgrow by mid-adolescence. If seizures are rare and only happen during sleep, avoiding the potential side effects of daily medication is usually the preferred approach.
When should a child start medication for SeLECTS?
Your neurologist may recommend starting daily medication if your child's seizures become frequent, occur during the day, or disrupt sleep and cause significant anxiety. Treatment is also considered if a child shows sudden struggles with language, reading, or school performance.
Will anti-seizure medication stop the spikes on my child's EEG?
Doctors generally focus on treating the physical seizures rather than the electrical spikes seen on an EEG. A child may have an EEG with many spikes, but if they are not having actual seizures and are doing well in school, medication may not be necessary.
What are the risks of using oxcarbazepine (Trileptal) for SeLECTS?
While oxcarbazepine is often well-tolerated, in some children with SeLECTS it can paradoxically worsen sleep spikes. This can lead to a sudden decline in school performance or loss of language skills, so parents should monitor their child closely if starting this medication.
Can we get Sulthiame (Ospolot) in the United States?
Sulthiame (Ospolot) is a standard medication used in Europe that is very effective at reducing EEG spikes in children with SeLECTS. However, it is not FDA-approved and is generally unavailable to patients in the United States.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my child's seizure frequency and history, why do you recommend 'watchful waiting' versus starting medication?
  2. 2.If we choose medication, why would you prefer one (e.g., Levetiracetam) over another (e.g., Oxcarbazepine) for my child?
  3. 3.Are you seeing any evidence of cognitive or language regression that would make you want to treat the 'spikes' even if seizures are rare?
  4. 4.What are the potential side effects for the specific medication you are recommending, and how will we monitor for them?
  5. 5.If we start a medication, how long will my child typically stay on it before we try to taper off?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Self-limited epilepsy with centro-temporal spikes: A study of 46 patients with unusual clinical manifestations.

    Galicchio S, Espeche A, Cersosimo R, et al.

    Epilepsy research 2021; (169()):106507 doi:10.1016/j.eplepsyres.2020.106507.

    PMID: 33296810
  2. 2

    Beta oscillations in the sensorimotor cortex correlate with disease and remission in benign epilepsy with centrotemporal spikes.

    Song DY, Stoyell SM, Ross EE, et al.

    Brain and behavior 2019; (9(3)):e01237 doi:10.1002/brb3.1237.

    PMID: 30790472
  3. 3

    Exploring the Correlations Between Language Impairments, Central Auditory Processing Disorder, Neuropsychiatric Functions, and Seizure Timing in Children With Self-Limited Epilepsy With Centrotemporal Spikes.

    Tin O, Saltık S, Kara HÇ, et al.

    Journal of child neurology 2025; (40(5)):324-331 doi:10.1177/08830738241304864.

    PMID: 39676505
  4. 4

    Sleep Related Epilepsy and Pharmacotherapy: An Insight.

    Kumar J, Solaiman A, Mahakkanukrauh P, et al.

    Frontiers in pharmacology 2018; (9()):1088 doi:10.3389/fphar.2018.01088.

    PMID: 30319421
  5. 5

    The Efficacy and Cognitive Impact of Perampanel Monotherapy in Patients with Self-Limited Epilepsy with Centrotemporal Spikes: A Retrospective Analysis.

    Yue X, Liu XM, Chen J, et al.

    Neuropsychiatric disease and treatment 2023; (19()):1263-1271 doi:10.2147/NDT.S410858.

    PMID: 37274142
  6. 6

    Nightly oral administration of topiramate for benign childhood epilepsy with centrotemporal spikes.

    Liu C, Song M, Wang J

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2016; (32(5)):839-43 doi:10.1007/s00381-016-3043-0.

    PMID: 26984807
  7. 7

    Clinical and electrophysiological predictors of behavioral disorders in patients with benign childhood epilepsy with centrotemporal spikes.

    Özgen Y, Güngör M, Kutlu M, Kara B

    Epilepsy & behavior : E&B 2021; (121(Pt A)):108037 doi:10.1016/j.yebeh.2021.108037.

    PMID: 34058495
  8. 8

    Alternations of neuromagnetic activity across neurocognitive core networks among benign childhood epilepsy with centrotemporal spikes: A multi-frequency MEG study.

    Wang S, Wang Y, Li Y, et al.

    Frontiers in neuroscience 2023; (17()):1101127 doi:10.3389/fnins.2023.1101127.

    PMID: 36908802
  9. 9

    ADHD and ADHD-related neural networks in benign epilepsy with centrotemporal spikes: A systematic review.

    Aricò M, Arigliani E, Giannotti F, Romani M

    Epilepsy & behavior : E&B 2020; (112()):107448 doi:10.1016/j.yebeh.2020.107448.

    PMID: 32916583
  10. 10

    Safety and efficacy of one-dose nocturnal levetiracetam for the treatment of self-limited epilepsy with centrotemporal spikes: a randomized clinical trial.

    Fan L, Shen Y, Zhang J, et al.

    Scientific reports 2025; (15(1)):34302 doi:10.1038/s41598-025-11906-x.

    PMID: 41034293
  11. 11

    Effects of levetiracetam and oxcarbazepine monotherapy on intellectual and cognitive development in children with benign epilepsy with centrotemporal spikes.

    Suo GH, Zheng YQ, Wu YJ, Tang JH

    Acta neurologica Belgica 2021; (121(5)):1265-1273 doi:10.1007/s13760-021-01613-5.

    PMID: 33590471
  12. 12

    Encephalopathy with status epilepticus during sleep (ESES) induced by oxcarbazepine in idiopathic focal epilepsy in childhood.

    Pavlidis E, Rubboli G, Nikanorova M, et al.

    Functional neurology 2015; (30(2)):139-41 doi:10.11138/fneur/2015.30.2.139.

    PMID: 26415787
  13. 13

    The fate of spikes in self-limited epilepsy with centrotemporal spikes: Are clinical and baseline EEG features effective?

    Günay Ç, Sarikaya Uzan G, Özsoy Ö, et al.

    Epilepsy research 2023; (193()):107165 doi:10.1016/j.eplepsyres.2023.107165.

    PMID: 37201400
  14. 14

    Influence of epileptic activity during sleep on cognitive performance in benign childhood epilepsy with centrotemporal spikes.

    Nissenkorn A, Pappo A, Feldmann Y, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2017; (21(6)):858-863 doi:10.1016/j.ejpn.2017.07.001.

    PMID: 28734769
  15. 15

    EEG resting state analysis of cortical sources in patients with benign epilepsy with centrotemporal spikes.

    Adebimpe A, Aarabi A, Bourel-Ponchel E, et al.

    NeuroImage. Clinical 2015; (9()):275-82 doi:10.1016/j.nicl.2015.08.014.

    PMID: 26509114

This page provides educational information about SeLECTS treatment strategies. Always consult your child's pediatric neurologist before starting, stopping, or changing any anti-seizure medication.

Get notified when new evidence is published on Self-limited epilepsy with centrotemporal spikes.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.